Adult Dosing

Nausea/vomiting

• 300 mg PO tid-qid

Pediatric Dosing

• Safety and effectiveness in pediatric patients have not been established

• Postoperative nausea and vomiting
• Nausea associated with gastroenteritis

• Hypersensitivity to any of the ingredients of the product
• Pediatric patients

• N/A

Renal Dose Adjustment (Based on CrCl)

• <70 mL/min: Consider decreasing dose or increasing dosing interval

Hepatic Dose Adjustment

• Hepatic impairment: Dose adjustments not defined

• Antiemetics may make diagnosis of appendicitis more difficult
• Cause drowsiness; advise patients not to operate motor vehicles or other dangerous machinery until their individual responses have been determined
• Concomitant use of alcohol may result in an adverse drug interaction
• Restore body fluids and electrolyte balance and treat underlying causative disease
• Elderly patients with renal impairment may need decreased doses or increased dosing interval
• Avoid use in children with uncomplicated vomiting. Extrapyramidal symptoms occurring secondary to trimethobenzamide may be confused with CNS symptoms of an undiagnosed primary disease responsible for vomiting
• Limit use to prolonged vomiting of known etiology
• Avoid use in children whose signs and symptoms could represent Reye's syndrome

Cautions: Use cautiously in

• Patients who have recently received other CNS-acting agents
• Alcohol use
• Dehydration
• Electrolyte abnormalities
• Debilitated patients
• Geriatric Population

Pregnancy Category:C

Breastfeeding: Safety unknown

• CV: Hypotension, prolonged QT interval
• CNS: Parkinson-like symptoms, mood depression, disorientation, headache, drowsiness, opisthotonos, dizziness, seizures, coma
• EENT: Blurred vision
• GI: Diarrhea, xerostomia
• HEMA: Blood dyscrasias
• HEPA: Jaundice, cholestasis
• LOCAL: Local pain, burning, stinging, redness and swelling (after injection)
• MUSC: Muscle cramps
• MISC: Hypersensitivity reactions

• Antiemetic; exact mechanism of action unknown; directly affects medullary chemoreceptor trigger zone to inhibit nausea
• Relative bioavailability 100%
• Metabolized by liver; CYP450: unknown
• Renally excreted: 30-50% (primarily unchanged); feces
• Half-life: 7-9 hrs

US Trade Name(s)

• Tigan

US Availability

trimethobenzamide (generic)

• CAPS: 300 mg

Tigan

• CAPS: 300 mg

Canadian Trade Name(s)

• N/A

Canadian Availability

• N/A

UK Trade Name(s)

• N/A

UK Availability

• N/A

Australian Trade Name(s)

• N/A

Australian Availability

• N/A

Gastrointestinal

Antiemetics

Anticholinergic Antiemetics

Pricing data from www.DrugStore.com in U.S.A.

• Tigan 300 MG CAPS [Bottle] (MONARCH PHARMACEUTICALS)
  30 mg = $60.99
  90 mg = $174.97

Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.

• Tigan 300 MG Oral Capsule (King Pharmaceuticals, Inc.)
• Tigan 300 MG Oral Capsule (Monarch Pharmaceuticals, Inc.)
• Trimethobenzamide hydrochloride 300 MG Oral Capsule (Actavis Totowa LLC)
• Trimethobenzamide hydrochloride 300 MG Oral Capsule (Mutual Pharmaceutical Company, Inc.)
• Trimethobenzamide hydrochloride 300 MG Oral Capsule (Rebel Distributors Corp.)